Rabbit Recombinant Monoclonal Peroxiredoxin 1/PAG antibody. Suitable for IHC-P, WB and reacts with Mouse, Human samples. Cited in 7 publications.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA
IHC-P | IP | WB | |
---|---|---|---|
Human | Tested | Not recommended | Tested |
Mouse | Tested | Not recommended | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/1000 - 1/4000 | Notes Perform antigen retrieval Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species Human | Dilution info 1/1000 - 1/4000 | Notes Perform antigen retrieval Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/10000 - 1/50000 | Notes - |
Species Human | Dilution info 1/10000 - 1/50000 | Notes - |
Select an associated product type
Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively. Plays a role in cell protection against oxidative stress by detoxifying peroxides and as sensor of hydrogen peroxide-mediated signaling events. Might participate in the signaling cascades of growth factors and tumor necrosis factor-alpha by regulating the intracellular concentrations of H(2)O(2) (PubMed:9497357). Reduces an intramolecular disulfide bond in GDPD5 that gates the ability to GDPD5 to drive postmitotic motor neuron differentiation (By similarity).
PAGA, PAGB, TDPX2, PRDX1, Peroxiredoxin-1, Natural killer cell-enhancing factor A, Proliferation-associated gene protein, Thioredoxin peroxidase 2, Thioredoxin-dependent peroxide reductase 2, Thioredoxin-dependent peroxiredoxin 1, NKEF-A, PAG
Rabbit Recombinant Monoclonal Peroxiredoxin 1/PAG antibody. Suitable for IHC-P, WB and reacts with Mouse, Human samples. Cited in 7 publications.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.
Peroxiredoxin 1 also known as PAG plays an important role as an antioxidant enzyme. It is part of the peroxiredoxin family with a molecular mass of around 22 kDa. This protein helps reduce hydrogen peroxide and organic hydroperoxides to water and corresponding alcohols using reducing equivalents provided by thiol-containing donor molecules. Peroxiredoxin 1/PAG expresses widely in human tissues and cells including liver and erythrocytes reflecting its involvement in cellular redox regulation.
Peroxiredoxin 1 helps maintain cellular homeostasis by protecting cells from oxidative stress. It forms homodimers or interacts with other proteins to propagate cellular responses to changes in redox state. As an important member of the antioxidant defense mechanism it contributes to cellular signaling through modulation of hydrogen peroxide signaling pathways. The protein also plays a role in cell proliferation and apoptosis making it significant for cellular health and disease prevention.
Peroxiredoxin 1 participates in critical processes such as the MAPK signaling and TGF-beta pathways. It interacts with MAPK-related proteins influencing cell survival and growth. Peroxiredoxin 1 indirectly modulates downstream signaling molecules that contribute to cellular responses. In these pathways the protein's antioxidant properties allow regulation of reactive oxygen species levels which directly affect cellular signaling cascades.
Peroxiredoxin 1 is relevant to cancer and neurodegenerative disorders. Overexpression or misregulation of this protein has been linked to various cancers where it potentially interacts with oncogenic proteins like c-Myc to promote tumor progression. Additionally abnormal levels of Peroxiredoxin 1 associate with neurodegenerative diseases as oxidative stress is a common factor in their pathology. These connections suggest the protein as a promising target in therapeutic interventions for these diseases.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
ab109498 was shown to specifically react with Peroxiredoxin 1/PAG when Peroxiredoxin 1/PAG knockout samples were used. Wild-type and Peroxiredoxin 1/PAG knockout samples were subjected to SDS-PAGE. ab109498 and Anti-GAPDH antibody [6C5] - Loading Control ab8245 (loading control to GAPDH) were both diluted 1/10 000 and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.
All lanes: Western blot - Anti-Peroxiredoxin 1/PAG antibody [EPR5433] (ab109498)
Predicted band size: 22 kDa
ab109498 Anti-Peroxiredoxin 1/PAG antibody [EPR5433] was shown to specifically react with Peroxiredoxin 1/PAG in wild-type HEK293T cells. Loss of signal was observed when knockout cell line Human PRDX1 (Peroxiredoxin 1/PAG) knockout HEK-293T cell line ab266842 (knockout cell lysate Human PRDX1 (Peroxiredoxin 1/PAG) knockout HEK-293T cell lysate ab257040) was used. Wild-type and Peroxiredoxin 1/PAG knockout samples were subjected to SDS-PAGE. ab109498 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-Peroxiredoxin 1/PAG antibody [EPR5433] (ab109498) at 1/1000 dilution
Lane 1: Wild-type HEK293T cell lysate at 20 µg
Lane 2: PRDX1 knockout HEK293T cell lysate at 20 µg
Lane 2: Western blot - Human PRDX1 (Peroxiredoxin 1/PAG) knockout HEK-293T cell line (Human PRDX1 (Peroxiredoxin 1/PAG) knockout HEK-293T cell line ab266842)
Lane 3: Jurkat cell lysate at 20 µg
All lanes: Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) at 1/10000 dilution
Predicted band size: 22 kDa, 41 kDa, 45 kDa, 78 kDa
Observed band size: 25 kDa, 26 kDa, 47 kDa, 49 kDa, 78 kDa
Blocking and diluting buffer and concentration: 5% NFDM/TBST
All lanes: Western blot - Anti-Peroxiredoxin 1/PAG antibody [EPR5433] (ab109498) at 1/10000 dilution
Lane 1: MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 2: K-562 (Human chronic myelogenous leukemia lymphoblast) whole cell lysate at 20 µg
Lane 3: NIH/3T3 (Mouse embryonic fibroblast) whole cell lysate at 20 µg
Lane 4: Mouse brain lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 22 kDa
Observed band size: 22 kDa
Exposure time: 10s
Immunohistochemical analysis of paraffin-embedded Human thyroid cancer tissue labeling Peroxiredoxin 1/PAG with ab109498 at 1/1000 (0.155 ug/ml) dilution. The section was incubated with ab109498 for 30 mins at room temperature and followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (Rabbit specific IHC polymer detection kit HRP/DAB ab209101). Counterstained with Hematoxylin.
Positive staining on the human thyroid cancer, performed on a Leica Biosystems BOND® RX instrument.
Secondary antibody only control: Rabbit specific IHC polymer detection kit HRP/DAB (Rabbit specific IHC polymer detection kit HRP/DAB ab209101)
Heat mediated antigen retrieval with Citrate buffer (pH 6.0, epitope retrieval solution 1) for 20 mins.
Immunohistochemical analysis of paraffin-embedded Mouse kidney tissue labeling Peroxiredoxin 1/PAG with ab109498 at 1/4000 (0.038 ug/ml) dilution. The section was incubated with ab109498 for 30 mins at room temperature and followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (Rabbit specific IHC polymer detection kit HRP/DAB ab209101). Counterstained with Hematoxylin.
Positive staining on the mouse kidney, performed on a Leica Biosystems BOND® RX instrument.
Secondary antibody only control: Rabbit specific IHC polymer detection kit HRP/DAB (Rabbit specific IHC polymer detection kit HRP/DAB ab209101)
Heat mediated antigen retrieval with Citrate buffer (pH 6.0, epitope retrieval solution 1) for 20 mins.
Image collected and cropped by CiteAb under a CC-BY license from the publication
Peroxiredoxin 1/PAG western blot using anti-Peroxiredoxin 1/PAG antibody [EPR5433] ab109498. Publication image and figure legend from Ziegler, Y. S., Moresco, J. J., et al., 2016, PLoS One, PubMed 27355404.
ab109498 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab109498 please see the product overview.
Identification of proteins in BC and MCF-10A cell secretomes.A. A workflow was established to analyze the secretomes of BC and benign mammary epithelial cells. B. Benign (MCF-10A), ERα-positive BC (MCF-7), and TNBC (MDA-MB-231, DT22, and DT28) cells were established in 3D cultures using Matrigel extracellular matrix. Live (top row) and fixed (bottom row) cultures were imaged by phase contrast or immunofluorescence, respectively. Markers of proliferation (Ki67-red), basement membrane (laminin-green), and nuclei (DAPI-blue) were utilized. C. 3D cultures of MCF-10A cells were exposed to CM from MCF-10A, MCF-7, MDA-MB-231, DT22, or DT28 cells. Proliferation (red) and nuclei (blue) are indicated by Ki67 and DAPI staining, respectively. Scale bars indicate 25 μm. D. 3D cultures described in panel C were analyzed to determine the percent of proliferating MCF-10A cells for each treatment. An asterisk (*) indicates a p-value <0.05. E. CM from each cell line was subjected to MS and compiled results are shown. F. CM from 3D cultures of BC and MCF-10A cells were subjected to Western blot analysis using antibodies to cathepsin D (CTSD), extracellular matrix protein 1 (ECM1), peroxiredoxin 1 (PRDX1), or 14-3-3 sigma (SFN). The number of spectral counts (SCs) is indicated above each lane. To visualize SFN, the CM was concentrated before blot. MDA-MB-231 and MCF-10A cells are labeled as 231 and 10A, respectively. (Abbreviations: BC = breast cancer, TNBC = triple negative breast cancer, 3D = three dimensional, CM = conditioned medium, MS = mass spectroscopy)
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com